Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: a systematic review and meta-analysis

References

• Hilliard NJ , JohnsonCN , ArmstrongSH , QuarlesS , WaitesKB. In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int. J. Antimicrob. Agents20(2), 136–140 (2002).
   PubMed Web of Science ®Google Scholar
• Draghi DC , SheehanDJ , HoganP , SahmDF. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother.49(12), 5024–5032 (2005).
   PubMed Web of Science ®Google Scholar
• Brickner SJ , BarbachynMR , HutchinsonDK , ManninenPR. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious Gram-positive infections. J. Med. Chem.51(7), 1981–1990 (2008).
   PubMed Web of Science ®Google Scholar
• Diekema DJ , JonesRN. Oxazolidinone antibiotics. Lancet358(9297), 1975–1982 (2001).
   PubMed Web of Science ®Google Scholar
• Farrell DJ , MendesRE , RossJE , SaderHS , JonesRN. LEADER program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob. Agents Chemother.55(8), 3684–3690 (2011).
   PubMed Web of Science ®Google Scholar
• Marchese A , SchitoG. Resistance patterns of lower respiratory tract pathogens in Europe. Int. J. Antimicrob. Agents16, 25–29 (2000).
   PubMed Web of Science ®Google Scholar
• Nagai K , AppelbaumPC , DaviesTAet al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and eastern European countries. Antimicrob. Agents Chemother.46(2), 371–377 (2002).
   PubMed Web of Science ®Google Scholar
• Felmingham D , ReinertRR , HirakataY , RodloffA. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother.50(Suppl. 2), S25–S37 (2002).
   PubMedGoogle Scholar
• De Neeling A , OverbeekB , HorrevortsA , LigtvoetE , GoettschW. Antibiotic use and resistance of Streptococcus pneumoniae in The Netherlands during the period 1994–1999. J. Antimicrob. Chemother.48(3), 441–444 (2001).
   PubMed Web of Science ®Google Scholar
• Farrell DJ , MendesRE , RossJE , JonesRN. Linezolid surveillance program results for 2008 (LEADER program for 2008). Diagn. Microbiol. Infect. Dis.65(4), 392–403 (2009).
   PubMed Web of Science ®Google Scholar
• Schito A , SchitoG , DebbiaEet al. Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999–2000. J. Chemother.15(3), 226–234 (2003).
   PubMed Web of Science ®Google Scholar
• Bolmstrom A , BallowC , QwarnstromA , BiedenbachD , JonesR. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox® antimicrobial potency study (ZAPS–Europe). Clin. Microbiol. Infect.8(12), 791–800 (2002).
   PubMed Web of Science ®Google Scholar
• Jones RN , FritscheTR , SaderHS , RossJE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis.59(3), 309–317 (2007).
   PubMed Web of Science ®Google Scholar
• Moher D , LiberatiA , TetzlaffJ , AltmanDG , PRISMAGroup. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.6(7), e1000097 (2009).
   PubMed Web of Science ®Google Scholar
• Stang A . Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol.25(9), 603–605 (2010).
   PubMed Web of Science ®Google Scholar
• Pakzad R , MalekifarP , ShateriZet al. Worldwide prevalence of microbial agents’ coinfection among COVID-19 patients: a comprehensive updated systematic review and meta-analysis. J. Clin. Lab. Anal.36(1), e24151 (2022).
   PubMed Web of Science ®Google Scholar
• Luna CM , PulidoL , NiedermanMSet al. Decreased relative risk of pneumococcal pneumonia during the last decade, a nested case–control study. Pneumonia (Nathan Qld.)10, 9 (2018).
   PubMedGoogle Scholar
• Cillóniz C , DominedòC , Garcia-VidalC , TorresA. Community-acquired pneumonia as an emergency condition. Curr. Opin. Crit. Care24(6), 531–539 (2018).
   PubMed Web of Science ®Google Scholar
• Shoji H , Vázquez-SánchezDA , Gonzalez-DiazAet al. Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016. Infect. Drug Resist.11, 1387–1400 (2018).
   PubMed Web of Science ®Google Scholar
• Ghaffar F , FriedlandIR , McCrackenGHJr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. J. Pediatr. Infect. Dis.18(7), 638–646 (1999).
   PubMed Web of Science ®Google Scholar
• Osowicki J , SteerAC. International survey of paediatric infectious diseases consultants on the management of community-acquired pneumonia complicated by pleural empyema. J. Paediatr. Child Health55(1), 66–73 (2019).
   PubMed Web of Science ®Google Scholar
• Jakhar SK , PandeyM , ShahDet al. Etiology and risk factors determining poor outcome of severe pneumonia in under-five children. Indian J. Pediatr.85(1), 20–24 (2018).
   PubMed Web of Science ®Google Scholar
• Lewandowska K , KuśJ. Community acquired pneumonia – treatment options according to the international recommendations. Wiad. Lek. (Warsaw, Poland: 1960)69(2 Pt 1), 139–144 (2016).
   PubMedGoogle Scholar
• Karchmer AW . Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US – an update. Clin. Infect. Dis.39(Suppl. 3), S142–S150 (2004).
   PubMedGoogle Scholar
• Jacobs MR . Streptococcus pneumoniae: epidemiology and patterns of resistance. Am. J. Med. Suppl.117(3), 3–15 (2004).
   Google Scholar
• Jean S-S , HsuehP-R. High burden of antimicrobial resistance in Asia. Int. J. Antimicrob. Agents37(4), 291–295 (2011).
   PubMed Web of Science ®Google Scholar
• Isaacson G , AronoffSC. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. Int. J. Pediatr. Otorhinolaryngol.72(5), 647–651 (2008).
   PubMed Web of Science ®Google Scholar
• Perry CM , JarvisB. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs61(4), 525–551 (2001).
   PubMed Web of Science ®Google Scholar
• Lin DF , ZhangYY , WuJFet al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int. J. Antimicrob. Agents32(3), 241–249 (2008).
   PubMed Web of Science ®Google Scholar
• Jones RN , KohnoS , OnoY , RossJE , YanagiharaK. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis.64(2), 191–201 (2009).
   PubMed Web of Science ®Google Scholar
• García-Castillo M , MorosiniMI , ValverdeAet al. Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. J. Antimicrob. Chemother.59(2), 301–304 (2007).
   PubMed Web of Science ®Google Scholar
• Kahlmeter G , BrownDF , GoldsteinFWet al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin. Microbiol. Infect.2(6), 501–503 (2006).
   Google Scholar
• Feng J , LupienA , GingrasHet al. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res.19(7), 1214–1223 (2009).
   PubMed Web of Science ®Google Scholar
• Saiman L , GoldfarbJ , KaplanSAet al. Safety and tolerability of linezolid in children. J. Pediatr. Infect. Dis.22(Suppl. 9), S193–S200 (2003).
   Google Scholar
• Chien JW , KuciaML , SalataRA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin. Infect. Dis.30(1), 146–151 (2000).
   PubMed Web of Science ®Google Scholar
• Clemett D , MarkhamA. Linezolid. Drugs59(4), 815–827; discussion 828 (2000).
   PubMed Web of Science ®Google Scholar
• Bishop E , MelvaniS , HowdenBP , CharlesPG , GraysonML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother.50(4), 1599–1602 (2006).
   PubMed Web of Science ®Google Scholar
• San Pedro GS , CammarataSK , OliphantTH , TodiscoT. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand. J. Infect. Dis.34(10), 720–728 (2002).
   PubMedGoogle Scholar